Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0003289,
umls-concept:C0030685,
umls-concept:C0036751,
umls-concept:C0037925,
umls-concept:C0038585,
umls-concept:C0087111,
umls-concept:C0127400,
umls-concept:C0205191,
umls-concept:C0391871,
umls-concept:C0597357,
umls-concept:C0680255,
umls-concept:C0851285,
umls-concept:C1280500,
umls-concept:C1283071,
umls-concept:C1704448,
umls-concept:C1963578
|
pubmed:issue |
1
|
pubmed:dateCreated |
1986-9-16
|
pubmed:abstractText |
Regulation of the release of substance P (SP) by the coexisting neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) in the ventral spinal cord and the effects of chronic antidepressant treatment mediated changes in serotonin metabolism on the regulation, were examined. The K+ (40 mmol/l) evoked release of (SP) from slices of the ventral spinal cord of the rat was potentiated by (5-HT) applied to 100 mumol/l concentration. This effect was blocked by the serotoninergic antagonists methysergide (10 mumol/l), methiotepin (10 mumol/l) and fully blocked by ketanserin (10 mumol/l). Thus the 5-HT receptor which regulates the release of SP appears to belong to the type-2 5-HT receptors. Chronic treatment with the selective serotonin uptake inhibitor zimelidine (14 days, 2 X 10 mumol/kg/day, p.o.) lowered the tissue levels of the 5-HT metabolite: 5-hydroxyindol acetic acid (5-HIAA) and elevated the tissue levels of SP in both the ventral and dorsal spinal cord as compared to that in the vehicle treated group (14 days, 2 X 5 ml saline/kg/day, p.o.). The decrease in the 5-HIAA levels after chronic zimelidine treatment was quantitatively similar in the dorsal (33%, p less than 0.01) and ventral (31%, p less than 0.05) spinal cord. The increase in SP levels after chronic zimelidine treatment was more pronounced in the ventral cord (80%, p less than 0.01) where the majority of the SP containing nerve endings also contain 5-HT, than in the dorsal spinal cord (22% increase in SP, p less than 0.05), where only a minor fraction of the SP-containing nerve endings shows a 5-HT/SP coexistence.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antidepressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroxyindoleacetic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Imipramine,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Serotonin,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Substance P,
http://linkedlifedata.com/resource/pubmed/chemical/Zimeldine
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0028-1298
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
333
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1-6
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2426604-Animals,
pubmed-meshheading:2426604-Antidepressive Agents,
pubmed-meshheading:2426604-Hydroxyindoleacetic Acid,
pubmed-meshheading:2426604-Imipramine,
pubmed-meshheading:2426604-Male,
pubmed-meshheading:2426604-Rats,
pubmed-meshheading:2426604-Rats, Inbred Strains,
pubmed-meshheading:2426604-Receptors, Serotonin,
pubmed-meshheading:2426604-Serotonin,
pubmed-meshheading:2426604-Serotonin Antagonists,
pubmed-meshheading:2426604-Spinal Cord,
pubmed-meshheading:2426604-Substance P,
pubmed-meshheading:2426604-Zimeldine
|
pubmed:year |
1986
|
pubmed:articleTitle |
Serotonin type-2 receptor mediated regulation of substance P release in the ventral spinal cord and the effects of chronic antidepressant treatment.
|
pubmed:publicationType |
Journal Article,
In Vitro
|